-
2 weeks ago | 
hmpgloballearningnetwork.com | Hannah Musick
A recent real-world analysis comparing chimeric antigen receptor (CAR) T-cell therapy to standard non–CAR T treatments for relapsed/refractory mantle cell lymphoma (R/R MCL) found that patients receiving CAR T therapy experienced fewer follow-up treatments, longer treatment-free intervals, and reduced health care costs. The study included 2835 patients treated with non–CAR T standard of care and 122 patients treated with CAR T therapy, all with at least 2 prior lines of therapy.
-
1 month ago | 
hmpgloballearningnetwork.com | Hannah Musick
A qualitative meta-synthesis explores the barriers, facilitators, and lived experiences of immigrants with disabilities (IWDs) accessing health care in the US and Canada, revealing structural and cultural obstacles that hinder access and highlighting the need for policy reforms to improve health care services for this marginalized population.
-
1 month ago | 
hmpgloballearningnetwork.com | Hannah Musick
New research explores the cost-efficiency and expanded access of biosimilar bevacizumab in Medicare for patients with metastatic colorectal (mCRC) and non-small cell lung cancer (mNSCLC), revealing substantial cost savings and potential for treating additional patients on a budget-neutral basis. Bevacizumab, a VEGF inhibitor originally approved for metastatic colorectal cancer, is now used for various solid tumor indications including mCRC and mNSCLC.
-
1 month ago | 
hmpgloballearningnetwork.com | Hannah Musick
The US Department of Veterans Affairs (VA) is accelerating deployment of the Federal Electronic Health Record (EHR) system at VA medical facilities, with complete implementation expected by 2031 for seamless integration with the Department of Defense (DOD). The VA announced via press release plans to deploy the Federal EHR system at 9 more medical facilities, bringing the total to 13 by 2026 and all VA facilities by 2031.
-
1 month ago | 
hmpgloballearningnetwork.com | Hannah Musick
In a study of adults aged 50 and older hospitalized with respiratory syncytial virus (RSV) infection, those with chronic medical conditions, especially older adults, had higher hospitalization rates, suggesting they may benefit most from RSV vaccination. In 2023, the CDC recommended RSV vaccination for adults aged 60 years and older through shared clinical decision-making, while clinical trials for younger age groups are ongoing.
-
1 month ago | 
hmpgloballearningnetwork.com | Hannah Musick
A review published in the Journal of the European Academy of Dermatology and Venereology explores the impact of skin diseases on mental health and the availability of resources globally to support individuals with skin conditions, highlighting the importance of culturally sensitive approaches and leveraging digital health technologies for widespread adoption.
-
1 month ago | 
hmpgloballearningnetwork.com | Hannah Musick
A Class II recall has been issued for Ergocalciferol (Vitamin D) Supplement, 10 mcg (400 Units) per 0.05 mL Oral Syringe, manufactured by Westminster and repackaged by Safecor Health, LLC. The recall affects 3069 oral syringes from Lot #24300812 (Exp. 01/31/2025) and Lot #24530836 (Exp. 07/19/2025). The recall was initiated due to a defective delivery system, where leakage was observed in unit-dose syringes, potentially leading to inaccurate dosing and reduced effectiveness of the supplement.
-
1 month ago | 
hmpgloballearningnetwork.com | Hannah Musick
A Class II recall has been initiated for Morphine Sulfate Extended-Release Tablets, 100 mg, manufactured by Ohm Laboratories Inc. and distributed by Sun Pharmaceutical Industries, Inc. The recall affects 9840 bottles, each containing 100 tablets, distributed nationwide. The affected product comes from Lot #AD16615, with an expiration date of July 2025. The recall was prompted by failed dissolution specifications, which could lead to improper drug release and potential under-dosing or overdose risks.
-
1 month ago | 
hmpgloballearningnetwork.com | Hannah Musick
A study on the effects of a modified Atkins diet (MAD) on patients with multiple sclerosis (MS) reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in MS therapy. Previous research has shown that diet can impact immune processes in MS, and ketogenic diets have demonstrated anti-inflammatory effects in animal models of MS. However, the effects of these diets on humans with MS are still unclear.
-
1 month ago | 
hmpgloballearningnetwork.com | Hannah Musick
In a study of patients with early relapsing multiple sclerosis (MS), treatment with ozanimod showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS. Patients with relapsing MS often experience accelerated brain volume loss, which can be linked to cognitive impairment.
